Labcorp Brings Breakthrough Diagnostic to Identify Platinum-Resistant Ovarian Cancer Patients

Labcorp announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic designed to identify patients with platinum-resistant ovarian cancer who may be eligible for…

Continue Reading Labcorp Brings Breakthrough Diagnostic to Identify Platinum-Resistant Ovarian Cancer Patients

Breakthrough Lung Cancer Therapy Advances: Ifinatamab Deruxtecan Receives FDA Priority Review for Small Cell Lung Cancer

Daiichi Sankyo and Merck announced a significant regulatory milestone with the FDA's acceptance and Priority Review of ifinatamab deruxtecan (I-DXd), a potentially first-in-class therapeutic targeting an innovative cancer pathway. According…

Continue Reading Breakthrough Lung Cancer Therapy Advances: Ifinatamab Deruxtecan Receives FDA Priority Review for Small Cell Lung Cancer